Sandoz wins a ruling on US pegfilgrastim

Sandoz has scored a victory over Amgen in US patent-infringement proceedings involving the originator’s “only patent that remains at issue” in the firms’ long-running dispute over Sandoz’ filgrastim and pegfilgrastim biosimilars.